10-Q · June 22, 2026
INVO Fertility, Inc. reported a revenue of $1.583 million for Q4 2026, falling short of estimates by 17.9%. The company posted an EPS of -40.4, which was significantly below the anticipated -22.0. Despite an overall…
Earnings analysis · 10-Q
IVF earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not provide current-period revenue, margins, EPS, cash flow, balance-sheet figures, segment results, or quantitative guidance, so operating trends cannot be assessed from the filing text…
Read full summary
The extracted 10-Q does not provide current-period revenue, margins, EPS, cash flow, balance-sheet figures, segment results, or quantitative guidance, so operating trends cannot be assessed from the filing text supplied. The principal disclosure is negative: management concluded that disclosure controls and internal control over financial reporting were not effective as of June 30, 2026 due to 2 material weaknesses. Remediation is underway, including added accounting resources and planned improvements to segregation of duties, documentation, training, and review procedures.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control remediation underway
Management stated that disclosure controls and procedures were not effective as of June 30, 2026, and described an ongoing remediation program.
-
Accounting resources being expanded
The company added accounting resources and plans additional personnel, training, documentation, supervision, and more frequent financial-statement reviews to address the deficiencies as of June 30, 2026.
-
No material legal proceedings
The company reported that it was not currently subject to any material legal proceedings as of August 14, 2026.
-
No unregistered equity sales
The filing reported no unregistered sales of equity securities during the quarter ended June 30, 2026.
What to watch
-
Material weaknesses in internal controls
As of June 30, 2026, internal control over financial reporting was not effective because of 2 material weaknesses: limited segregation of duties and insufficient accounting resources for complex transactions.
-
Potential financial misstatements
The identified control deficiencies could result in material misstatements of significant accounts and disclosures that are not prevented or detected, according to the filing dated August 14, 2026.
-
Limited risk-factor disclosure
Item 1A states that smaller reporting companies are not required to provide risk-factor disclosures, so this 10-Q does not provide a detailed update to evaluate changes versus the prior filing as of August 14, 2026.
Management's outlook
No quantitative revenue or EPS outlook was provided in the filing; the extracted filing is focused on controls and other information rather than operating results.
Earlier filings 3
10-K · June 12, 2026
INVO Fertility, Inc. reported fiscal year 2025 revenue of $6,841,250, a 5% increase from the previous year, despite an increase in operating losses. The company aims to expand clinic operations and fortify its financial…
10-K · June 2, 2026
INVO Fertility (IVF) is focused on expanding access to ART care by acquiring and operating fertility clinics, including those utilizing its proprietary INVOcell device. Despite a notable acquisition strategy, the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.